BioPharmSignal logoBioPharmSignal

Biotech News

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma (URGN)UroGen PharmaClinical readout

Phase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., Nov.

Related news

URGNUroGen Pharma2026-11-04 13:00 EST

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

BMEABiomea Fusion2026-10-13 20:08 EST

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

IMCRImmunocore Holdings plc2026-10-15 11:00 EST

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

BMYBMYBristol-Myers Squibb Company2026-10-19 10:59 EST

Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026

MGNXMacroGenics2026-10-15 20:05 EST

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

CGEMCullinan Therapeutics, Inc.2026-10-08 11:00 EST

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

URGNUroGen Pharma2026-10-19 12:00 EST

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

ACRVAcrivon Therapeutics2026-10-29 12:00 EST

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

View all latest news

UroGen Pharma

Uro-Oncology Franchise UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease. Commercial ZUSDURI...

Recent company news

URGNUroGen Pharma2026-11-04 13:00 EST

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

URGNUroGen Pharma2026-11-02 13:00 EST

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

URGNUroGen Pharma2026-10-28 12:00 EST

UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

URGNUroGen Pharma2026-10-27 22:00 EST

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

Stock data

Close
25.73 USD
Market cap
1.29B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States